Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.35 +7.3%	$2.41	$0.40 ▼ $3.10	$176.56M	2.13	1.41 million shs	1.45 million shs
EPRX Eupraxia Pharmaceuticals	$5.30 -1.8%	$4.79	$2.20 ▼ $6.20	$194.18M	1.51	11,620 shs	4,758 shs
TVGN Semper Paratus Acquisition	$1.00 +1.1%	$1.21	$0.26 ▼ $3.09	$181.93M	-0.76	591,443 shs	380,734 shs
VTVT vTv Therapeutics	$14.59 -2.4%	$15.90	$12.58 ▼ $26.99	$47.76M	0.57	2,943 shs	2,579 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+7.31%	-2.08%	-5.24%	+193.02%	+70.29%
EPRX Eupraxia Pharmaceuticals	-1.78%	-3.39%	-3.03%	+32.43%	+86.76%
TVGN Semper Paratus Acquisition	+1.07%	-5.67%	-20.01%	-1.00%	+56.23%
VTVT vTv Therapeutics	-1.68%	-5.44%	-3.12%	-35.04%	-3.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.0091 of 5 stars	3.5	1.0	4.7	1.9	1.7	1.3
EPRX Eupraxia Pharmaceuticals	2.5434 of 5 stars	3.6	2.0	0.0	2.6	0.0	0.6
TVGN Semper Paratus Acquisition	2.9982 of 5 stars	3.5	3.0	0.0	0.0	2.5	0.0
VTVT vTv Therapeutics	2.159 of 5 stars	3.5	5.0	0.0	1.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.75	144.68% Upside
EPRX Eupraxia Pharmaceuticals	3.17	Buy	$11.00	107.39% Upside
TVGN Semper Paratus Acquisition	3.00	Buy	$10.00	900.10% Upside
VTVT vTv Therapeutics	3.00	Buy	$35.50	143.32% Upside

Current Analyst Ratings Breakdown

Latest VTVT, EPRX, TVGN, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/24/2025	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/18/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
6/10/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$138.10M	1.37	$0.39 per share	6.05	($0.01) per share	-235.00
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	($0.09) per share	N/A
VTVT vTv Therapeutics	$1.02M	45.63	N/A	N/A	$4.48 per share	3.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.48	4.90	N/A	N/A	28.22%	-553.71%	32.21%	8/7/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.76	N/A	N/A	N/A	N/A	-367.73%	-112.23%	8/6/2025 (Estimated)
TVGN Semper Paratus Acquisition	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	8/4/2025 (Estimated)
VTVT vTv Therapeutics	-$18.46M	-$3.01	N/A	∞	N/A	N/A	-121.46%	-46.75%	8/6/2025 (Estimated)

Latest VTVT, EPRX, TVGN, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	N/A	VTVT vTv Therapeutics	-$0.85	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	CTMX CytomX Therapeutics	-$0.05	N/A	N/A	N/A	$19.10 million	N/A
8/6/2025	N/A	EPRX Eupraxia Pharmaceuticals	-$0.21	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	VTVT vTv Therapeutics	-$0.73	-$0.77	-$0.04	-$0.77	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.73	1.73
EPRX Eupraxia Pharmaceuticals	N/A	11.10	11.10
TVGN Semper Paratus Acquisition	N/A	0.35	0.35
VTVT vTv Therapeutics	N/A	7.39	7.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EPRX Eupraxia Pharmaceuticals	N/A
TVGN Semper Paratus Acquisition	N/A
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
EPRX Eupraxia Pharmaceuticals	N/A
TVGN Semper Paratus Acquisition	73.24%
VTVT vTv Therapeutics	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
TVGN Semper Paratus Acquisition	3	183.89 million	49.21 million	N/A
VTVT vTv Therapeutics	9	3.19 million	3.06 million	Not Optionable

VTVT, EPRX, TVGN, and CTMX Headlines

Recent News About These Companies

vTv Therapeutics (NASDAQ:VTVT) Share Price Passes Below 50 Day Moving Average - Here's Why

July 26, 2025 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving Average - Time to Sell?

July 17, 2025 | marketbeat.com

vTv Therapeutics Inc (VTVT) Share Chat - Investing.com UK

June 29, 2025 | uk.investing.com

VTVT - vTv Therapeutics Inc Class A Chart - Morningstar

June 27, 2025 | morningstar.comM

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

June 11, 2025 | globenewswire.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.comT

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.comQ

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation

April 9, 2025 | msn.com

vTv Therapeutics cleared to resume clinical trial of diabetes therapy

March 26, 2025 | ncbiotech.orgN

vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year

March 21, 2025 | markets.businessinsider.com

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

March 18, 2025 | finanznachrichten.de

Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

March 18, 2025 | markets.businessinsider.com

vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program

March 17, 2025 | markets.businessinsider.com

vTv Therapeutics stock surges on FDA update

March 17, 2025 | au.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, EPRX, TVGN, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.35 +0.16 (+7.31%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.40 +0.04 (+1.91%)

As of 08/1/2025 07:41 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.30 -0.10 (-1.78%)

Closing price 08/1/2025 03:50 PM Eastern

Extended Trading

$5.58 +0.27 (+5.18%)

As of 08/1/2025 05:16 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Semper Paratus Acquisition NASDAQ:TVGN

$1.00 +0.01 (+1.07%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.01 +0.01 (+1.01%)

As of 08/1/2025 07:56 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

vTv Therapeutics NASDAQ:VTVT

$14.59 -0.36 (-2.41%)

Closing price 08/1/2025 03:42 PM Eastern

Extended Trading

$14.57 -0.02 (-0.14%)

As of 08/1/2025 04:10 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time